Vipul Gupta discusses balloon assisted coiling in ruptured cerebral aneurysms and mechanical thrombectomy with stent retrievers. He summarizes several key randomized controlled trials that demonstrated the benefits of endovascular therapy using stent retrievers over standard medical therapy alone for acute ischemic stroke. The trials showed significant improvements in revascularization, clinical outcomes, and mortality. The 2015 AHA/ASA guidelines recommend endovascular therapy with stent retrievers for select patients within 6 hours of stroke onset based on the evidence from these trials. The document also reviews techniques for mechanical thrombectomy and strategies to optimize outcomes.
Mechanical thrombectomy for acute ischemic stroke (temporary stroke) is a minimally invasive endovascular procedure to remove blood clots from larger vessels in the brain.
Who is it recommended for?
Mechanical thrombectomy is indicated for patients who:
1. Had an Acute ischemic stroke due to LAO
2. Has failed intravenous thrombolysis
3. Have temporarily or permanent disabilities with the the below mentioned.
Complications:
a. Paralysis or loss of movement in muscles
b. Difficulty when talking or swallowing
c. Memory loss or difficulty in processing thoughts, reasoning or making decisions/judgements
d. Pain or numbness in affected parts
e. Change in moods, behaviour and self-care ability.
However, consulting physicians and surgeons decide if Mechanical thrombectomy for Acute Ischemic (temporary) Stroke is a suitable option for the patient. The decision is made based on various factors, such as age, severity of the stroke, time and test results. Eligible patients should receive intravenous alteplase without delay even if mechanical thrombectomy is being considered.
Recovery after Mechanical thrombectomy:
Recovery of the patient depends on:
1. Overall condition
2. Severity of the stroke
3. Severity of the symptoms
Patients are seen usually walking within 24 hours.of the procedure, but if the injury is severe then doctors recommend a couple of days rest with physiotherapy and rehabilitation.
Benefits of Mechanical thrombectomy for acute ischemic stroke are:
1. Greater Efficacy
2. Cost Effective
3. Larger Treatment window (up to 24 hours)
4. Short Hospital stay and rehabilitation
Mechanical thrombectomy for acute ischemic stroke (temporary stroke) is a minimally invasive endovascular procedure to remove blood clots from larger vessels in the brain.
Diffusion-weighted imaging or computerized tomography perfusion assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neurointervention with Trevo (DAWN) trial methods
Int J Stroke. 2017 Aug;12(6):641-652.
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
N Engl J Med. 2018 Jan 4;378(1):11-21.
A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3)
Int J Stroke. 2017 Oct;12(8):896-905.
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
N Engl J Med. 2018 Feb 22;378(8):708-718.
Mechanical thrombectomy for acute ischemic stroke (temporary stroke) is a minimally invasive endovascular procedure to remove blood clots from larger vessels in the brain.
Who is it recommended for?
Mechanical thrombectomy is indicated for patients who:
1. Had an Acute ischemic stroke due to LAO
2. Has failed intravenous thrombolysis
3. Have temporarily or permanent disabilities with the the below mentioned.
Complications:
a. Paralysis or loss of movement in muscles
b. Difficulty when talking or swallowing
c. Memory loss or difficulty in processing thoughts, reasoning or making decisions/judgements
d. Pain or numbness in affected parts
e. Change in moods, behaviour and self-care ability.
However, consulting physicians and surgeons decide if Mechanical thrombectomy for Acute Ischemic (temporary) Stroke is a suitable option for the patient. The decision is made based on various factors, such as age, severity of the stroke, time and test results. Eligible patients should receive intravenous alteplase without delay even if mechanical thrombectomy is being considered.
Recovery after Mechanical thrombectomy:
Recovery of the patient depends on:
1. Overall condition
2. Severity of the stroke
3. Severity of the symptoms
Patients are seen usually walking within 24 hours.of the procedure, but if the injury is severe then doctors recommend a couple of days rest with physiotherapy and rehabilitation.
Benefits of Mechanical thrombectomy for acute ischemic stroke are:
1. Greater Efficacy
2. Cost Effective
3. Larger Treatment window (up to 24 hours)
4. Short Hospital stay and rehabilitation
Mechanical thrombectomy for acute ischemic stroke (temporary stroke) is a minimally invasive endovascular procedure to remove blood clots from larger vessels in the brain.
Diffusion-weighted imaging or computerized tomography perfusion assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neurointervention with Trevo (DAWN) trial methods
Int J Stroke. 2017 Aug;12(6):641-652.
Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
N Engl J Med. 2018 Jan 4;378(1):11-21.
A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3)
Int J Stroke. 2017 Oct;12(8):896-905.
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
N Engl J Med. 2018 Feb 22;378(8):708-718.
Carotid artery disease is commonly seen in association with atherosclerosis and complicate the situation. clearcut guidelines with necessary surgical details are provided in presentations.
I am a Neurosurgeon with advanced training in Interventional vascular Neurosurgery(FINR) from Zurich, Switzerland, and FMINS-Fellowship in minimally invasive and Endoscopic Neurosurgery from Germany.
I am presently working in Columbia asia hospitals, Bangalore.
My areas of interest are Vascular Neurosurgery, Stroke specialist, interventional neuroradiology,
Arteriovenous Malformations are one of the toughest cerebral pathologies to manage with high post op mortality and morbidity. this powerpoint contains classification, grading and managment of various severity of AVMs
Carotid artery disease is commonly seen in association with atherosclerosis and complicate the situation. clearcut guidelines with necessary surgical details are provided in presentations.
I am a Neurosurgeon with advanced training in Interventional vascular Neurosurgery(FINR) from Zurich, Switzerland, and FMINS-Fellowship in minimally invasive and Endoscopic Neurosurgery from Germany.
I am presently working in Columbia asia hospitals, Bangalore.
My areas of interest are Vascular Neurosurgery, Stroke specialist, interventional neuroradiology,
Arteriovenous Malformations are one of the toughest cerebral pathologies to manage with high post op mortality and morbidity. this powerpoint contains classification, grading and managment of various severity of AVMs
EVOLUTION IN CARDIAC RESYNCHRONIZATION THERAPY
Moving towards Leadless pacing mainly in cases with difficult coronary sinus anatomy, where placing the LV lead is difficult.
"Revolutionizing Stroke Care: Endovascular Therapy and Neuro Intervention in Acute Ischemic Stroke with Dr. Ganesh"
🌟 Greetings, everyone! Dr. Ganesh here, and today, we're exploring a groundbreaking topic that's transforming the landscape of stroke care: Endovascular Therapy and Neuro Intervention in Acute Ischemic Stroke (AIS). Whether you're a healthcare professional, a patient, or simply intrigued by medical advancements, this discussion is tailored for you.
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low...Shadab Ahmad
The role of transcatheter aortic valve replacement (TAVR) in the treatment of patients with severe, symptomatic aortic stenosis has evolved on the basis of evidence from clinical trials.
Previous randomized trials of TAVR with both balloon-expandable valves and self-expanding valves showed that, in patients who were at intermediate or high risk for death with surgery, TAVR was either superior or noninferior to standard therapies, including surgical aortic-valve replacement.
However, most patients with severe aortic stenosis are at low surgical risk, and there is insufficient evidence regarding the comparison of TAVR with surgery in such patients.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Mechanical thrombectomy with stent retriever
1. BALLOON ASSISTED COILING IN
RUPTURED CEREBRAL ANEURYSMS
Vipul Gupta
Neurointerventional Surgery
Artemis Hospital, Gurgaon
Mechanical thrombectomy with stent retriever-
How do we do it
3. Randomised trials – General criterion
• Randomised (Intervention Vs Standard
medical therapy)
• Documented site of occlusion.
• Time based: 6 hrs (initiation of IA therapy)
• Small Core
• Predominantly stent retrievers.
4. MR CLEAN Trial
Netherlands, 2015
ESCAPE Trial
Canadian, 2015
EXTEND-IA Trial
Australian, 2015
SWIFT PRIME Trial
USA, 2015
REVASCAT Trial
Spanish, 2015
10. AHA/ ASA guideline 2015:
Patients should receive endovascular therapy with a stent
retriever if they meet all the following criteria (Class I; Level of
Evidence A). (New recommendation):
prestroke mRS score 0 to 1
acute ischemic stroke receiving intravenous r-tPA within 4.5
hours of onset
causative occlusion of the internal carotid artery or proximal
MCA (M1)
age ≥18 years
NIHSS score of ≥6
ASPECTS of ≥ 6
treatment can be initiated (groin puncture) within 6 hours of
symptom onset
11. AHA/ ASA guideline:
Carefully selected patients with anterior circulation
occlusion who have contraindications to intravenous r-
tPA, endovascular therapy with stent retrievers
completed within 6 hours of stroke onset is reasonable
(Class IIa; Level of Evidence C).
Carefully selected patients with acute ischemic stroke in
whom treatment can be initiated (groin puncture) within 6
hours of symptom onset and who have causative
occlusion of the M2 or M3 portion of the MCAs, anterior
cerebral arteries, vertebral arteries, basilar artery, or
posterior cerebral arteries (Class IIb; Level of Evidence
C)
12. AHA/ ASA guideline:
Stent retrieval may be reasonable for patients
with acute is initiated (groin puncture) within 6
hours of ischemic stroke in whom treatment can
be of symptom onset and who have prestroke
mRS score of >1, ASPECTS >1, ASPECTS <6, or
NIHSS score <6 and causative occlusion of the
internal carotid artery or proximal MCA (M1)
Observing patients after intravenous r-tPA to
assess for clinical response before pursuing
endovascular therapy is not required to achieve
beneficial outcomes and is not recommended.
(Class III; Level of Evidence B-R).
13. STRUCTURE of STROKE care systems:
Should be transported rapidly to the closest available
certified primary strokecenter or comprehensive stroke
center
Regional systems of stroke care: Initial emergency
care (IV tPA)→ Centers capable of performing
endovascular stroke treatment.
Experienced stroke center with rapid access to
cerebral angiography and qualified neuro-
interventionalists.
14. Beyond 6 hours – Should you consider MT?
ESCAPE: up to 12-hours – positive trial
6 hours
49 patients
rate ratio, 1.7; (95% CI, 0.7 to 4.0)
Not significant; however few numbers.
REVASCAT: upto 12 hours, positive trial
Data not provided.
Recent analysis – 7.3 hours…
15. Techniques
A. Stent retriever
B. Stent retriever with BCG
C. Stent retriever with DAC (ARTS), SOLUMBRA
D. ADAPT
E. Other
Various choices of stent retrievers or similar devices ..
16. Solitaire (ev3)- 2012, Trevo (Stryker), Revive™ SE (Codman),
Etc…. etc…..
Stentretrievers - Stent or stent-like system for
clot removal
17. STEPS
• Check clinical status
• Don’t wait for lines ,
complete draping
• Local anesthesia.- anesthetist
in lab – sedation
• If restless , consider GA
• But should be done without
delay , avoiding drop in BP
• If IV tPA – single wall
puncture, micropuncture set
(closure device)
• 8 F short sheath
• 3000-5000 U heparin (not if
tPA)
18. • Remember arch anatomy from CTA
• 8F BGC , co-axial 5F Vert
• If very tortuous – SIM 2 with Amplatz
exchange in ECA/CCA
• Coaxially over at proximal ICA
(straight segment)
• (Cello BCG – more navigable)
19.
20. • Clot traversed with microwire
• Traxcess 012-014 – with a loop if
possible
• Take care of temproal branch,
perforators
• Microcatheter is then threaded
• Distal position confirmed by v.
small amt of contrast injection.
• Also tells us about positioning of
stent
• Solitaire (4 x 40) or (6 x 30 terminal
ICA) is deployed across the clot.
• DSA - Flow across clot is
demonstrated
• Allow stent to engage clot (3- 5
mins)
21.
22. •Re-sheath the
proximal aspect of
the stent before
retrieval.
•Inflate Balloon
(proximal flow arrest)
•Aspirate (60 cc
syringe)
•Take out the stent
along with RHV
•Remove RHV and
aspirate vigorously
23. • DSA
• Cleaning an resheathing the stent, MC
preparation should go on simultaneously
• 3 passes
• End-point – TICI IIb/IIIa
• If not - stop, alternative methods, ?? PTA
• Closure device
• Stroke ICU
24. •68/M, DM, HTN, CAD, underwent PTCA to LAD
•Admitted for surgery of aortic stenosis.
•Double anti-platelets was stopped
•Patient developed acute onset right side weakness
with aphasia.
IV- tPA given, no improvement
28. 8:07 AM
Patient made gradual recovery
Left LL 4/5 and UL 3/5 - 30 day follow up
mRS at 90 days- 0
29. • 60 years old female.
• h/o hypertension and hypothyroidism
• Acute onset left hemiparesis and left facial weakness
• No history of LOC/seizures
• CT Brain , perfusion and angio done 6 1/2 hours after ictus.
33. 980 patients: GA in 44%
Poor neurological outcome:
OR 2.3 (with GA)
Higher mortality: OR 1.6 (with
GA)
1956 patients: GA in 41%
Good outcome: OR 0.5 (with GA)
Higher mortality: OR 2.5 (with GA)
Successful angiographic outcome:
OR 0.5 (with GA)
• Sedation vs Intubation for Endovascular Stroke TreAtment
Trial (SIESTA) is a prospective, randomised controlled,
monocentric, two-armed, comparative trial.
• ESOC - We did not see a difference in the primary outcome of
change in NIHSS [National Institutes of Health Stroke Severity]
score at 24 hours between patients receiving general
anesthesia and those given conscious sedation," he
concluded. "However, this data is preliminary and we don't
yet have the main secondary outcome of modified Rankin
scores at 3 months. These will be reported at the World
Stroke Congress in October
34. NASA BGC Registry (339)
USA, Multicenter, Retrospective
79/149 77/149 68/189 30/149
self reported
61/189 55/189
P < .001 P = .02 P = .02
34
Imrpoving the outcomes
• Technique
36. Solitaire™ FR Device vs. Trevo™* Device
Design Overview
**Competitive Testing Report FD2815.
***Covidien Testing Data: FD2601A
Trevo™* Device
Solitaire™ DeviceImages property of Covidien. Image is an artistic rendering
and not a n exact depiction of the Solitaire™ FR Device.
Image property of Covidien. Image is an artistic
rendering and not a n exact depiction of the Trevo™
Device.
• The Solitaire™ FR device - Parametric™ design that may
provide multiple planes of clot contact.
•Trevo - straight cut tube ; struts of the Trevo™* device to cut
into the clot
Consistent
Cell Size
Variable Cell
Size
Force-
Flex™
Straight-
Cut
37. Tips to getting the clot on first pass
• Long stent 4mm X 40 mm solitaire
42. Technique
• Stent retriever with BCG
• Simple – easy to learn
• Results getting better
• Each step as a protocol –
everybody in team in sync
• Avoid experimentation in
initial phase
• Other factors (selection,
time …) more important
43. For more information on:
STROKE & NEUROVASCULAR INTERVENTIONS:
URL:
www.sanif.co.in
Facebook:
https://www.facebook.com/strokeawarenessindia
https://www.facebook.com/vipul.gupta.35175
Twitter
https://twitter.com/drvipulgupta25
LinkedIN
https://in.linkedin.com/pub/dr-vipul-gupta/51/8a1/25a
YouTube
Channel: Stroke & Neurovascular Interventions
www.youtube.com/c/StrokeNeurovascularInterventionsfoundation
Dr Vipul Gupta